Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
==========================================================================================================================

* David J Sullivan
* Massimo Franchini
* Michael J. Joyner
* Arturo Casadevall
* Daniele Focosi

## Abstract

The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates the continued relevance of COVID- 19 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing on early outpatients and immunocompromised recipients, with high neutralizing antibody (nAb) titer units. In this analysis we systematically reviewed Omicron-neutralizing plasma activity data, and found that approximately 47% (424/902) of CCP from unvaccinated pre-Omicron donors neutralizes Omicron BA.1 with a very low geomean of geometric mean titers for 50% neutralization GM(GMT50) of about 13, representing a more than 20-fold reduction from WA-1 neutralization. Two doses of mRNA vaccines in nonconvalescent subjects had a similar 50% percent neutralization with Omicron BA.1 neutralization GM(GMT(50)) of about 27. However, plasma from vaccinees recovered from either previous pre-Omicron variants of concern infection, Omicron BA.1 infection, or third-dose uninfected vaccinees was nearly 100% neutralizing against Omicron BA.1, BA.2 and BA.4/5 with GM(GMT(50)) all over 189, 10 times higher than pre-Omicron CCP. Fully vaccinated and post-BA.1 plasma (Vax-CCP) had GM(GMT50) over 450 for BA.4/5 and over 1500 for BA.1 and BA.2. These findings have implications for both CCP stocks collected in prior pandemic periods and plans to restart CCP collections. Thus, Vax-CCP provides an effective tool to combat ongoing variants that defeat therapeutic monoclonal antibodies.

Keywords
*   COVID19
*   Omicron
*   convalescent plasma
*   vaccine
*   neutralizing antibodies

## Introduction

The SARS-CoV-2 Omicron variant of concern (VOC) (originally named VUI-21NOV-01 by Public Health England and belonging to GISAID clade GRA(B.1.1.529+BA.*) was first reported on November 8, 2021 in South Africa, and shortly thereafter was also detected all around the world. Omicron mutations impact 27% of T cell epitopes 1 and 31% of B cell epitopes of the Spike protein, while percentages for other VOC were much lower 2. The Omicron variant has further evolved to several sublineages which are named by PANGO phylogeny using the BA alias: the BA.1 wave of Winter 2021-2022 has been suddenly replaced by BA.2 and BA.2.12.1 in Spring 2022, and by the BA.4 and BA.5 waves in Summer 2022.

The VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are delivered) and is initiating an unexpected boost in COVID19 convalescent plasma (CCP) usage, with Omicron being treated as a shifted novel virus instead of a SARS-CoV-2 variant drift. Two years into the pandemics, we are back to the starting line for some therapeutic classes. Specifically, Omicron escapes viral neutralization by most monoclonal antibodies (mAbs) authorized to date with the lone exception of bebtelovimab 3. Despite the development of promising oral small-molecule antivirals (molnupiravir and nirmatrelvir), the logistical and economical hurdles for deploying these drugs worldwide has prevented their immediate and widespread availability, and concerns remain regarding both molnupiravir (both safety4 and efficacy 5) and nirmatrelvir (efficacy), expecially in immunocompromised subjects. CCP was used as a frontline treatment from the very beginning of the pandemic. Efficacy outcomes have been mixed to date, with most failures explained by low dose, late usage, or both, but efficacy of high-titer CCP has been definitively proven in outpatients with mild disease stages 6, 7. Neutralizing antibody (nAb) efficacy against VOC remains a prerequisite to support CCP usage, which can now be collected from vaccinated convalescents, including donors recovered from breakthrough infections (so-called “hybrid plasma” or “Vax-CCP”)8: pre-Omicron evidence suggest that those nAbs have higher titers and are more effective against VOCs than those from unvaccinated convalescents 9, 10. From a regulatory viewpoint, to date, plasma from vaccinees that have never been convalescent does not fall within the FDA emergency use authorization

There are tens of different vaccine schedules theoretically possible according to EMA and FDA approvals, including a number of homologous or heterologous boosts, but the most commonly delivered schedules in the western hemisphere have been: 1) BNT162b2 or mRNA-1273 for 2 doses eventually followed by a homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost; and 3) Ad26.COV2.S for 1 dose eventually followed by a BNT162b2 boost 11. Many more inactivated vaccines have been in use in low-and-middle income countries (LMIC), which are target regions for CCP therapy: this is feasible given the lower number of patients at risk for disease progression there (lower incidences of obesity, diabetes, and hypertension, and lower median age) and the already widespread occurrence of collection and transfusion facilities. Most blood donors there have already received the vaccine schedule before, after or without having been infected, with a nAb titer generally declining over months 12. Hence identifying the settings where the nAb titer is highest will definitively increase the efficacy of CCP collections. Variations in nAb titers against a given SARS-CoV-2 strain are usually reported as fold-changes in geometric mean titer of antibodies neutralizing 50% of cytopathic effect (GMT50) compared to wild-type strains: nevertheless, fold-changes for groups that include non-responders can lead to highly artificial results and possibly over-interpretation. Rigorous studies have hence reported the percentage of responders as primary outcome and provided fold-changes of GMT50 where calculation is reasonable (100% responders in both arms) 13.

To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford University Coronavirus Antiviral & Resistance Database, but as of July 24, 2022 the tables there summarizing “Convalescent plasma” and “Vaccinee plasma” ([https://covdb.stanford.edu/search-drdb](https://covdb.stanford.edu/search-drdb)) do not dissect the different heterologous or homologous vaccination schemes, the simultaneous occurrence of vaccination and convalescence, or the time from infection/vaccine to neutralization assay. Consequently, a more in-depth analysis is needed to better stratify CCP types.

## Methods

On August 11, 2022, we searched PubMed, medRxiv and bioRxiv for research investigating the efficacy of CCP (either from vaccinated or unvaccinated donors) against SARS-CoV-2 VOC Omicron (pre)published after December 1, 2019, using English language as the only restriction. In PubMed we used the search query “(“convalescent plasma” or “convalescent serum”) AND (“neutralization” or “neutralizing”) AND “SARS-CoV-2”, while in bioRxiv and medRxiv we searched for abstract or title containing “convalescent, SARS-CoV-2, neutralization” (match all words). When a preprint was published, the latter was used for analysis. We also screened the reference lists of reviewed articles for additional studies not captured in our initial literature search. Articles underwent evaluation for inclusion by two assessors (D.F. and D.J.S.) and disagreements were resolved by a third senior assessor (A.C.). We excluded review articles, meta- analyses, studies reporting antibody levels by serological assays other than neutralization, as well as studies exclusively analyzing nAbs in vaccine-elicited plasma/serum from non-convalescent subjects. In unvaccinated subjects, convalescence was annotated according to infecting sublineage (pre-VOC Alpha, VOC Alpha, VOC Beta, VOC Delta, or VOC Omicron BA.1 sublineages). Given the heterologous immunity that develops after vaccination in convalescents, the infecting lineage was not annotated in vaccine recipients. In vaccinees, strata were created for 2 homologous doses, 3 homologous doses, or post- COVID-19 and post-vaccination (Vax-CCP). The type of viral assay (live or pseudovirus), time interval to blood sample, geometric mean, minimum and maximum neutralizing 50% dilutional titer for WA-1 (pre- Alpha wild-type) and Omicron sublineages BA.1, BA.2 and BA.4/5, and number out of total that neutralized Omicron was abstracted from study text, graphs and tables.

Statistical significance between log10 transformed geometric study means was investigated using Tukey’s test.

## Results

Our literature search identified 31 studies dealing with the original Omicron lineage (BA.1), that were then manually mined for relevant details: the PRISMA flowchart for study selection is provided in Figure 1. Given the urgency to assess efficacy against the upcoming VOC Omicron, many studies (with a few exceptions14–17) relied on Omicron BA.1 pseudovirus neutralization assays, which, as opposed to live authentic virus neutralization assays, are scalable, do not require BSL-3 facilities, and provide results in less than 1 week. Plasma dilutions were expressed in the studies as GMT50 of nAb, and fold-reduction in GMT50 compared to wild-type SARS-CoV-2 (e.g., WA-1) was the most common way of reporting changes, which reduces variability due to differences in the neutralization assays used. In comparing the large number of diverse studies with more than 100-fold plasma dilutional titers, we took the geometric mean of the individual study GMT50, deriving a geomean of GMT50 (GM(GMT50)).

![Figure 1](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F1.medium.gif)

[Figure 1](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F1)

Figure 1 
PRISMA flowchart for the current study.

Figure 2 and Table 1 summarize that neutralizing activity to WA-1 from CCP collected from subjects infected with pre-Alpha SARS-CoV-2 (Supplementary Table 1), Alpha VOC (Supplementary Table 2), Beta VOC (Supplementary Table 3), Delta VOC (Supplementary Table 4) or plasma from nonconvalescent subjects vaccinated with 2 mRNA vaccine doses (Supplementary Tables 5 and 6). The same plasma types computed a geometric mean of multiple GMT50 from many studies with about a 20-fold reduction against BA.1 geomeans compared to wild-type SARS-CoV-2 geomeans. CCP from uninfected vaccinees receiving a third vaccine dose registered a geomean of the GMT(50) of 2,588 (or 10- fold higher nAb geomean of the GMT50) to pre-alpha CCP viral assays. In this group the nAb geomean of the GMT50 fold-reduction against BA.1 was 9, but importantly the geomean of the GMT(50) was close to 300, similar to WA-1 inhibition by WA-1 CCP. The approximately 21-fold reduction in geomean of the GMT(50) from wild-type to BA.1 was reversed by the 10-15-fold increase in nAb geomean of the GMT(50) from either boosted (third-dose) vaccination or Vax-CCP.

View this table:
[Supplementary Table 1](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T3)

Supplementary Table 1 Synopsis of 27 *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron

View this table:
[Supplementary Table 2](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T4)

Supplementary Table 2 Synopsis of 5 in vitro studies investigating the efficacy of Alpha CCP against Omicron

View this table:
[Supplementary Table 3](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T5)

Supplementary Table 3 Synopsis of 5 *in vitro* studies investigating the efficacy of Beta CCP against Omicron.

View this table:
[Supplementary Table 4](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T6)

Supplementary Table 4 Synopsis of 7 *in vitro* studies investigating the efficacy of Delta CCP against Omicron.

View this table:
[Supplementary Table 5](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T7)

Supplementary Table 5 Synopsis of 22 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron.

View this table:
[Supplementary Table 6](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T8)

Supplementary Table 6 Synopsis of 9 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 mRNA-1273 doses against Omicron.

View this table:
[Supplementary Table 7](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T9)

Supplementary Table 7 Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2 BNT162b2 doses) subjects (Vax-CCP) against Omicron.

View this table:
[Supplementary Table 8](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T10)

Supplementary Table 8 Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 BNT162b2 doses against Omicron.

View this table:
[Supplementary Table 9](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T11)

Supplementary Table 9 Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 doses of mRNA-1273, AZD-1222 or Ad26.COV2 against BA.1. Because of diversity of vaccines the geomeans and sums were not computed.

View this table:
[Supplementary Table 10](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T12)

Supplementary Table 10 Synopsis of *in vitro* studies investigating the efficacy of plasma from (pre-omicron, BA.1 and BA.4/5 CCP) subjects against Omicron BA.1, BA.2 and BA.4/5.

View this table:
[Supplementary Table 11](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T13)

Supplementary Table 11 Synopsis of *in vitro* studies investigating the efficacy of plasma from (post-COVID-19-BA.1/full vacc plasma) subjects (Vax-CCP) against Omicron BA.1, BA.2 and BA.4/5.

View this table:
[Supplementary Table 12](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T14)

Supplementary Table 12 Synopsis of *in vitro* studies investigating the efficacy of plasma from (3 dose BNT162b2 plasma) subjects against Omicron BA.1, BA.2 and BA.4/5.

![Figure 2](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F2.medium.gif)

[Figure 2](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F2)

Figure 2 
Geometric mean neutralizing titers (GMT50) against WA-1 versus Omicron BA.1 by study for A) unvaccinated convalescent plasma and B) vaccinated plasma with or without COVID-19. Geomeans for entire study groups with neutralization of WA-1 in filled circles and of Omicron BA.1 in empty circles with geomeans, fold reduction (FR) above data, and number of studies above x-axis. All geomeans are not statistically significant in difference by multiple comparison in Tukey’s test.

View this table:
[Table 1](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T1)

Table 1 Comparison of WA-1 to Omicron BA.1 nAb and percent with any Omicron BA.1 nAb amongst VOC CCP and vaccination status.

In addition to the nAb GMT50 levels showing potency, the percentage of individuals within a study cohort positive for any level of BA.1 neutralization shows the likelihood of a possible donation having anti-BA.1 activity. All studies but one tested a limited number of 20 to 40 individuals. The pre-Alpha CCP showed that most (18 of 27 studies) had fewer than 50% of individuals tested within a study with measurable BA.1 neutralizing activity: only 2 out of 27 studies indicated that 100% of individuals tested showed BA.1 neutralization (Figure 3). Likewise, most of the studies investigating Alpha and Beta CCP showed similar percent with nAb. Delta CCP had 6 of 7 studies with more than 50% BA.1 neutralization. The plasma from studies of the 2-dose mRNA vaccines indicated a more uniform distributive increase in percent of individual patients with measurable Omicron BA.1 nAb’s. The stark contrast is pre-Omicron Vax-CCP, where 14 of 17 studies had 100% of individuals tested with anti-BA.1 nAb. The 3-dose vaccinee studies similarly had 12 of 17 studies with 100% measurable nAb.

![Figure 3](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F3.medium.gif)

[Figure 3](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F3)

Figure 3 
Percent of individual plasma samples in each study showing any titer of Omicron BA.1 neutralization. The percent of samples within a study condition which neutralized Omicron BA.1 graphed in increasing percentages with the number of samples tested on the right y axis. A) pre-Alpha CCP neutralization of Omicron BA.1; B) Alpha, Beta and Delta CCP neutralization of Omicron BA.1 C) 2 dose mRNA vaccines neutralization of Omicron BA.1 D) post-COVID-19/post-vaccine (Vax-CCP) and uninfected 3-dose vaccine neutralization of Omicron BA.1.

Five studies directly compared anti-WA-1 to BA.1 nAb titers in nonvaccinated pre-Alpha, Alpha, Beta, and Delta CCP, and vaccinated plasma with the same nAb assay (Figure 4). nAb GMT50 against WA-1 was higher for Alpha CCP but lower for Beta CCP. nAb geomean of the GMT(50) against BA.1 was actually highest for delta CCP with geomean levels of 6, 6, 10 for pre-Alpha, Alpha and Delta (Figure 4, panel A). In these 5 studies, nAb geomean of the GMT(50) rose from 2-dose vaccinations to Vax-CCP to the 3-dose boosted vaccination. Importantly, for nAb, geomean of the GMT(50) against BA.1 were 14 to 103 to 195, respectively (Figure 4, panel B).

![Figure 4](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F4.medium.gif)

[Figure 4](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F4)

Figure 4 
Geometric mean neutralizing titers (GMT50) of anti-WA.1 or anti-Omicron BA.1 neutralizing antibodies in plasma samples from 5 studies investigating diverse SARS-CoV-2 infecting lineage or vaccination status. 5 studies characterized A) pre-Alpha, Alpha, Beta and Delta CCP for Omicron BA.1 nAb compared to WA-1, and also B) 2 or 3 doses BNT162b plasma, as well as post-COVID-19 plus BNT162b vaccine (Vax-CCP). C) 9 additional studies looked at the same vaccine conditions in the first 5 comparing WA-1 nAb to Omicron BA.1 nAb.

Another set of 9 matched vaccination studies inclusive of plasma collected after 2- and 3-dose schedules, as well as Vax-CCP, depicted a 20-fold rise in the geomean of the GMT(50) of anti-BA.1 nAb from the 2- dose vaccine to post COVID-19 vaccinees, and a 21-fold increase after the third vaccine dose. The pattern was similar for nAb geomean of the GMT(50) against WA-1 (Figure 4, panel C).

The AZD1222, 3-dose mRNA-1273 and Ad26.COV2 vaccines were understudied, with 3 or less independent studies at different time points, reported in Table 10. The GMT50 nAb to BA.1 after 3-mRNA-1273 doses ranged 60 to 2000, with a 5-to-15-fold reduction compared with WA-1. GMT50 of anti- BA.1 nAbs after AZD1222 vaccine was modest (∼10 to 20), as with Ad26.COV2 vaccine (∼20 to 40). Two studies reported on post-COVID-19/post-mRNA-1273 with nAb GMT50 against BA.1 of 38 and 272. Studies with 100% of individual patient samples neutralizing BA.1 included 2 3-dose mRNA-1273 studies, one AZD1222 study, and one post-COVID-19/post-mRNA-1273 study.

Few data exist for comparisons among different vaccine boosts. For CoronaVac® (SinoVac), three doses led to 5.1 fold reduction in anti-BA.1 nAb GMT compared to wild-type 18, while for Sputnik V nAb titer moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3 months after a boost with Sputnik Light 19, 20. These *in vitro* findings have been largely confirmed *in vivo*, where prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination, protects against BA.1 re-infection 21.

Eleven studies analyzed the efficacy of CCP and Vax-CCP against Omicron sublineages other than BA.1, i.e. BA.2 and BA.4/5 (summarized in Table 2, Figure 5 and supplement Table 10, 11 and 12). Pre-Omicron (mainly Delta) CCP neutralized less than 40% of BA.1, BA.2 and BA.4/5. Unvaccinated individuals in 3 studies only with BA.1 primary infections poorly neutralized WA-1, with about 75% neutralizations of BA.1, BA.2 and BA.4/5. The 3 vaccine doses of BNT162b2 in 8 studies had a 7-, 6- and 16-fold reduction from WA-1 GM(GMT50) of 3,247 with percent of neutralizations all over 95%. Individuals from 11 populations with a BA.1 VaxCCP had a 2-, 2- and 8-fold reduction for WA-1 GM(GMT50) of 3578, with 99% Omicron neutralizations. Importantly, GM(GMT50) of BA.1 Vax-CCP was more than 1.5 times higher than that of pre-alpha CCP for WA-1. Omicron BA.1, BA.2 and BA.4/5 percent neutralization was over 99% for each. In conclusion, BA.1-Vax- CCP was both high-titer and high neutralization percent.

View this table:
[Table 2](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/T2)

Table 2 Efficacy of CCP, vaccinee plasma and Vax-CCP expressed as GMT50 against Omicron sublineages.

![Figure 5](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F5.medium.gif)

[Figure 5](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F5)

Figure 5 
Geometric mean neutralizing titers (GMT50) against WA-1 versus Omicron BA.1, BA.2 or BA.4/5 for A) boosted vaccinated plasma with or without BA.1 COVID-19 and B) unvaccinated preomicron or BA.1 CCP. Geomeans for entire study groups with neutralization of WA-1 in filled circles with Omicron in empty circles with geomeans and fold reduction (FR) above data and number of studies above x-axis. All geomeans are not statistically significant in difference by multiple comparison in Tukey’s test. The percent of samples within a study condition which neutralized Omicron graphed in increasing percentages with the number of samples tested on the right y axis. C) uninfected 3-dose vaccine neutralization of Omicron BA.1, BA.2 and BA.4/5.; D) post-COVID-19-BA.1/post-vaccine (Vax-CCP).

These studies largely confirm that Omicron CCP *per se* is poorly effective against the cognate or other Omicron sublineages22 (with the lone exception of cross-reactions among lineages sharing L452 mutations23 and broad-spectrum nAbs elicited by BA.524). By contrast, both the homologous and the heterologous efficacy of Omicron Vax-CCP is universally preserved 15, 25. Despite evidence that concentrated pooled human IgGs from convalescent and vaccinated donors have 5-fold reduced potency against BA.5 compared to wild-type SARS-CoV-2 26, such Vax-CCP derivative is devoid of IgA and IgM nAbs. These findings have important implications if a Vax-CCP program is to be re-launched at the time of BA.2 and BA.4/5 waves. In particular, the emerging R346X-harboring BA.4.6, BA.4.7, and BA.5.9 sublineages show 1.5-1.9-fold reduction in GMT50 by BA.1/2 Vax-CCP and 2.4-2.6 reduction by BA.5 Vax-CCP 27. Of interest, Vax-CCP after 2 doses remains superior to 4-dose vaccinee plasma in terms of nAb titers, and Vax-CCP with 3 vaccine doses is not consistently superior to Vax-CCP after 2 vaccines doses28.

Differences exist among neutralization assay protocols used across studies. These differences are placed in context once fold-reductions and percent neutralizations are used as reporting measures. The relative geometric mean titer with minimum and maximum titer levels is an alternative perspective. The live virus assays can be sorted from the pseudovirus assays along with the minimum and maximum extracted from the graphs or reported in data from the manuscripts. In general, about 80% of the live virus compared to pseudovirus overlap in dilutional titer magnitude with the pseudovirus assays outlier measurement consistently higher in range from a few studies (Figure 6). However, in some cases the minimum reported is not the limit of detection or quantification, but the lowest number in a group of SARS-CoV-2 antibody positive participants. Graphical depiction of the minimum and maximum dilutional titers are shown in Supplementary Figures 1-11.

![Supplementary Figure 1](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F7.medium.gif)

[Supplementary Figure 1](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F7)

Supplementary Figure 1 
Alternative graphing of Supplementary Table 1 and Figure 2A. 27 *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA- 1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 2](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F8.medium.gif)

[Supplementary Figure 2](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F8)

Supplementary Figure 2 
Alternative graphing of Supplementary Table 2 and Figure 2A. 5 *in vitro* studies investigating the efficacy of Alpha CCP against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 3](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F9.medium.gif)

[Supplementary Figure 3](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F9)

Supplementary Figure 3 
Alternative graphing of Supplementary Table 3 and Figure 2A. 5 *in vitro* studies investigating the efficacy of Beta CCP against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 4](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F10.medium.gif)

[Supplementary Figure 4](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F10)

Supplementary Figure 4 
Alternative graphing of Supplementary Table 4 and Figure 2A. 7 *in vitro* studies investigating the efficacy of Delta CCP against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 5](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F11.medium.gif)

[Supplementary Figure 5](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F11)

Supplementary Figure 5 
Alternative graphing of Supplementary Table 5 and Figure 2B. 22 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 6](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F12.medium.gif)

[Supplementary Figure 6](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F12)

Supplementary Figure 6 
Alternative graphing of Supplementary Table 6 and Figure 2B. 9 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 mRNA-1273 doses against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 7](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F13.medium.gif)

[Supplementary Figure 7](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F13)

Supplementary Figure 7 
Alternative graphing of Supplementary Table 7 and Figure 2B. 17 *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2 BNT162b2 doses) subjects (VaxCCP) against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 8](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F14.medium.gif)

[Supplementary Figure 8](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F14)

Supplementary Figure 8 
Alternative graphing of Supplementary Table 8 and Figure 2B. 17 *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 BNT162b2 doses against Omicron with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 9](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F15.medium.gif)

[Supplementary Figure 9](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F15)

Supplementary Figure 9 
Alternative graphing of Supplementary Table 10 and Figure 5. 7 *in vitro* studies investigating the efficacy of plasma from (pre-omicron, BA.1 and BA.4/5 CCP) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 10](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F16.medium.gif)

[Supplementary Figure 10](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F16)

Supplementary Figure 10 
Alternative graphing of Supplement table 11 and Figure 5. 9 *in vitro* studies investigating the efficacy of plasma from (post-COVID-19-BA.1/full vacc plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Supplementary Figure 11](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F17.medium.gif)

[Supplementary Figure 11](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F17)

Supplementary Figure 11 
Alternative graphing of Supplementary Table 12 and Figure 5. 8 *in vitro* studies investigating the efficacy of plasma from (3 dose BNT162b2 plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT50 from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT50 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

![Figure 6](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2021.12.24.21268317/F6.medium.gif)

[Figure 6](http://medrxiv.org/content/early/2022/08/22/2021.12.24.21268317/F6)

Figure 6 
GMT50 from each study with minimum and maximum dilution titer also shown. Live virus assays are on the left and pseudoviral assays on the right. A) pre-alpha CCP against WA-1, B) post COVID-19/Vax against WA-1. C) 3 dose BNT 162b2 against WA-1, D) post COVID-19 BA.1/Vac against WA-1, E) pre-alpha CCP against omicron BA.1, F) post COVID-19/Vax against Omicron BA.1. G) 3 dose BNT 162b2 against Omicron BA.1, H) post COVID-19 BA.1/Vac against Omicron BA.1, I) post COVID-19 BA.1/Vac against Omicron BA.2 J) post COVID-19 BA.1/Vac against BA.4/5.

## Discussion

Since nAbs are by definition antiviral, CCP with a high nAb GMT50 is preferable, and there is now strong clinical evidence that nAb titers correlate with clinical benefit in randomized clinical trials6, 7. Although nAb titers correlate with vaccine efficacy29, 30, it is important to keep in mind that SARS-CoV-2-binding non-neutralizing antibodies in CCP can similarly provide protection via Fc-mediated functions 31, 32. However, such functions are harder to measure and no automated assay exists for use in clinical laboratories. Hence, whereas the presence of a high nAb GMT50 in CCP is evidence for antibody effectiveness *in vitro*, the absence of nAb titer does not imply lack of protection *in vivo* where Fc effects mediate protection by other mechanisms such as antibody-dependent cell-mediated cytotoxicity, complement activation and phagocytosis.

The mechanism by which CCP from vaccinated COVID-19 convalescent individuals better neutralizes Omicron lineages is probably a combination of higher amounts of nAb and broader antibody specificity. Higher amounts of antibody could neutralize antigenically different variants through the law of mass action 33, whereby even lower affinity antibodies elicited to earlier variants would bind to the Omicron variant as mass compensates for reduced binding strength to drive the reaction forward. In addition, vaccinated COVID-19 convalescent individuals would have experienced SARS-CoV-2 protein in two antigenically different forms: as part of intact infective virions generated *in vivo* during an infectious process and as antigens in vaccine preparations. As the immune system processes the same antigen in different forms, there are numerous opportunities for processing the protein in different ways that can diversify the specificity of the immune response and thus increase the likelihood of eliciting antibodies that react with variant proteins. Structurally, it has been shown that third dose mRNA vaccination induces mostly class 1/2 antibodies encoded by IGHV1-58;IGHJ3-1 and IGHV1-69;IGHJ4-1 germlines, but not the IGHV2-5;IGHJ3-1 germline, i.e. broadly cross-reactive Class 3 antibodies seen after infection 34.

Our analysis provides strong evidence that, unlike what has been observed in Syrian hamster models 35, CCP from unvaccinated donors is unlikely (less than 50%) to have any measurable Omicron neutralization. Although the nAb GMT50 threshold for clinical utility remains poorly defined, it is noticeable that low BA.1 nAb GMT50 were generally detected in CCP after infection from pre-Omicron VOCs.

However, despite the huge heterogeneity of vaccine schedules, CCP from vaccinated and COVID-19 convalescent individuals (Vax-CCP) consistently harbors high nAb titers against BA.1 and novel sublineages if collected up to 6 months since last event (either vaccine dose or infection). These Omicron neutralizing levels are comparable in dilutional titers to that of WA-1 CCP neutralizing WA-1, but their prevalence is much higher at this time, facilitating recruitment of suitable donors. Pre-Omicron CCP boosted with WA-1-type vaccines induces heterologous immunity that effectively neutralizes Omicron in the same assays which rule in or out therapeutic anti-Spike monoclonal antibodies. Consequently, prescreening of Vax-CCP donors for nAb titers is not necessary, and qualification of Vax-CCP units remains advisable only within clinical trials. A more objective way to assess previous infection (convalescence) would be by measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly 36, 37. Previous symptomatic infection and vaccination can be established by collecting past medical history (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring rapidly declining anti-N antibodies. Although there is no formal evidence for this, it is likely that asymptomatic infection (leading to lower nAb levels in pre-Omicron studies) also leads to lower nAb levels after vaccination compared to symptomatic infection, given that disease severity correlates with nAb titer 38, 39: hence asymptomatically infected donors missed by investigating PMH are also less likely to be useful.

The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several authorities, including the FDA, do not currently allow collection from such donors for CCP therapy on the basis that the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior to the polyclonal anti-Spike-only response induced by vaccines. This may be a false premise for recipients of inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, where efficacy against Omicron is largely reduced 18, 20, 40, but the impact of boost doses is still unreported at the time of writing. Table 1 and Table 9 clearly show that 3-doses of BNT162b2 are enough to restore nAb levels against Omicron in the absence of SARS-CoV-2 infection.

Another point to consider is that information on nAb levels after the third vaccine dose has been almost exclusively investigated for only 1 month of follow-up, while studies on convalescents extend to more than 6 months. At present, it seems hence advisable to start from convalescent vaccinees rather than uninfected 3-dose vaccinees. This is also confirmed by immune escape reported *in vivo* after usage of vaccine (non-convalescent) plasma 41 despite very high nAb titres, likely due to restricted antigen specificity. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than the approved, short schedules42–45, but this remain to be confirmed in larger series. The same is true for breakthrough infections from Alpha or Delta VOC in fully BNT162b2 vaccinated subjects46, although variation in time from infection due to successive waves is a major confounder.

With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins collected from regular donors could become a more standardized alternative to CCP, but their efficacy to date (at the peak of the vaccination campaign) is still 16-fold reduced against Omicron compared to wild-type SARS-CoV-247, and such preparations include only IgG and not IgM and IgA, which have powerful SARS- CoV-2 activity 48, 49. Nevertheless, the FDA recently reported efficacy of hyperimmune serum against BA.1, BA.2, BA.3, BA.2.12.1, and BA.4/5 50.

CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one would prefer RCT evidence of efficacy against Omicron before deployment, there is concern that variants are generated so rapidly that by the time such trials commence this variant could be replaced by another. Given the success of CCP in 2 outpatient RCTs in reducing disease progression or hospitalization6, 7 and the loss of major mAb therapies due to Omicron antigenic changes, the high titers in 2022 omicron CCP collected from vaccinated convalescents provides an immediate option for COVID-19, especially in LMIC. Given the reduced hospitalization rate with Omicron compared to Delta 51, it is even more relevant to identify patient subsets at risk of progression in order to minimize the number needed to treat to prevent a single hospitalization. Using the same indications for use of mAb therapies while using the same (now unused) in-hospital facilities seems a logical approach.

We declare we have no conflict of interest related to this manuscript.

## Supporting information

Supplementary Dataset [[supplements/268317_file02.xlsx]](pending:yes)

## Data Availability

All data produced are available online at PubMed, medRxiv and bioRxiv.

## Funding Information

The analysis was supported by the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (D.S), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1) (A.C).

## Author contributions

D.F. and M.J.J. conceived the manuscript; D.F., D.J.S. and M.F. analyzed the literature, curated tables and wrote manuscripts; M.F. provided Figure 1; D.J.S. provided Figures 2-5.A.C. and M.J.J. revised the manuscript.

## Data availability statement

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

## Acknowledgements

none.

## Footnotes

*   changed author orders, added 1 main figure and 11 supplementary figures

*   Received December 24, 2021.
*   Revision received August 19, 2022.
*   Accepted August 22, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Ahmed SF, Quadeer AA, McKay M. SARS-CoV-2 T cell responses are expected to remain robust against Omicron. Viruses 14, 79 (2022).
    
    

2.  2.Bernasconi A, et al. Report on Omicron Spike mutations on epitopes and immunological/epidemiological/kinetics effects from literature. Accessed at [https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770) on July 23, 2022.) (2021).
    
    

3.  3.Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis, (2022).
    
    

4.  4.Zhou S, et al. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. The Journal of Infectious Diseases 224, 415–419 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiab247&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33961695&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

5.  5. Jayk Bernal A, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 386, 509–520 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

6.  6.Libster R, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med 384, 610–618 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2033700&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

7.  7.Sullivan D, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med, (2021).
    
    

8.  8.Vickers MA, et al. Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors. Transfusion 61, 2099–2106 (2021).
    
    

9.  9.Schmidt F, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512–516 (2021).
    
    

10. 10.Di Germanio C, et al. Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants. Transfusion 62, 563–569 (2021).
    
    

11. 11.Munro APS, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet 398, 2258–2276 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(21)02717-3/ATTACHMENT/B46F0D22-54E3-48A2-A676-52E85F5D4A32/MMC2.PDF&link_type=DOI) 

12. 12.Franchini M, et al. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors. Transfusion 62, 1171–1176 (2022).
    
    

13. 13.Jacobsen H, et al. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. 2021.2012.2021.21267898 (2021).
    
    

14. 14.Planas D, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

15. 15.Bekliz M, et al. Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants. doi:2021.2012.2028.21268491 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2028.21268491&link_type=DOI) 

16. 16.Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med 386, 698–700 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35021005&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

17. 17.Muik A, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678–680 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

18. 18.Zhao X, et al. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents. doi:2021.2012.2016.472391 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2016.472391&link_type=DOI) 

19. 19.Dolzhikova IV, et al. Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant. doi:2021.2012.2017.21267976 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2017.21267976&link_type=DOI) 

20. 20.Bowen JE, et al. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. doi:2022.2003.2015.484542 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2003.2015.484542&link_type=DOI) 

21. 21.Carazo S, et al. Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination. doi:2022.2004.2029.22274455 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2004.2029.22274455&link_type=DOI) 

22. 22.Turelli P, et al. Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing activity.doi:2022.2005.2002.22274436 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2005.2002.22274436&link_type=DOI) 

23. 23.Qu P, et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. N Engl J Med 386, 2526–2528 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMc2206725&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35704428&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

24. 24.Richardson SI, et al. SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1. doi:2022.2007.2014.500039 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2007.2014.500039&link_type=DOI) 

25. 25.Zhou R, et al. Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses. Clin Transl Med 2, e720 (2022).
    
    

26. 26.Aggarwal A, et al. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. doi:2022.2007.2007.22277128 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2007.2007.22277128&link_type=DOI) 

27. 27.Jian F, et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. doi:2022.2008.2009.503384 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2008.2009.503384&link_type=DOI) 

28. 28.Xie X, Zou J, Kurhade C, Liu M, Ren P, Shi P-Y. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine. doi:2022.2007.2029.502055 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2007.2029.502055&link_type=DOI) 

29. 29.Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205–1211 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-021-01377-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

30. 30.Feng S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine 27, 2032–2040 (2021).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

31. 31.Gilbert PB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, eab3435 (2021).
    
    

32. 32.Earle KA, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2021.05.063&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

33. 33.Tyrrell DA. Neutralization of viruses by homologous immune serum. II. Theoretical study of the equilibrium state. The Journal of experimental medicine 97, 863–870 (1953).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamVtIjtzOjU6InJlc2lkIjtzOjg6Ijk3LzYvODYzIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDgvMjIvMjAyMS4xMi4yNC4yMTI2ODMxNy5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

34. 34.Andreano E, et al. COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response. doi:2022.2005.2009.491201 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2005.2009.491201&link_type=DOI) 

35. 35.Ryan KA, et al. Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant. doi:2021.2012.2024.474081 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2024.474081&link_type=DOI) 

36. 36.Krutikov M, et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. The Lancet Healthy Longevity, (2021).
    
    

37. 37.Amjadi MF, et al. Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination. doi:2021.2011.2002.21265750 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2011.2002.21265750&link_type=DOI) 

38. 38.Klein S, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 130, 6141–6150 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1172/JCI142004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32764200&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

39. 39.Focosi D, Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. European journal of haematology 107, 24–28 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/ejh.13630&link_type=DOI) 

40. 40.Yu X, et al. Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from neutralization induced by a third booster dose of vaccination. doi:2021.2012.2017.21267961 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2017.21267961&link_type=DOI) 

41. 41.Gachoud D, et al. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents. doi:2022.2004.2024.22274200 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2004.2024.22274200&link_type=DOI) 

42. 42.Chatterjee D, et al. SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Rep 38, 110429 (2022).
    
    

43. 43.Grunau B, et al. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. JAMA 327, 279–281 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

44. 44.Tauzin A, et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. medRxiv [Preprint], doi:2021.2003.2018.435972 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2003.2018.435972&link_type=DOI) 

45. 45.Skowronski DM, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Clin Infect Dis, ciac290 (2022).
    
    

46. 46.Miyamoto S, et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. doi:2021.2012.2028.21268481 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2028.21268481&link_type=DOI) 

47. 47.Focosi D, Franchini M. Passive immunotherapies for COVID-19: The subtle line between standard and hyperimmune immunoglobulins is getting invisible. Reviews in medical virology, e2341 (2022).
    
    

48. 48.Klingler J, et al. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. J Infect Dis 223, 957–970 (2020).
    
    

49. 49.Wang Z, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med, (2020).
    
    

50. 50.Awasthi M, Golding H, Khurana S. SARS-CoV-2 hyperimmune intravenous human immunoglobulins neutralizes Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3 and BA.4/BA.5 for treatment of COVID-19. Clinical Infectious Diseases, (2022).
    
    

51. 51.Wolter N, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa. Lancet 399, 437–446 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

52. 52.Zeng C, et al. Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv, 2021).
    
    

53. 53.Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

54. 54.Schmidt F, et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N Engl J Med 386, 599–601 (2022).
    
    

55. 55.Arien KK, et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. NPJ Vaccines 7, 35 (2022).
    
    

56. 56.Lusvarghi S, et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. Sci Transl Med, eabn8543 (2022).
    
    

57. 57.Hoffmann M, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185, 447–456 e411 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

58. 58.Zou J, et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat Commun 13, 852 (2022).
    
    

59. 59.Zhang L, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect 11, 1–5 (2022).
    
    

60. 60.Gruell H, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med 28, 477–480 (2022).
    
    

61. 61.Dejnirattisai W, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484 e415 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/J.CELL.2021.12.046&link_type=DOI) 

62. 62.Sheward DJ, et al. Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron). bioRxiv, doi:2021.2012.2019.473354 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2019.473354&link_type=DOI) 

63. 63.Tada T, et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine 78, 103944 (2022).
    
    

64. 64.Aggarwal A, et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv, doi:2021.2012.2014.21267772 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2014.21267772&link_type=DOI) 

65. 65.Zhao X, et al. Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. N Engl J Med 386, 894–896 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

66. 66.Bowen JE, et al. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. bioRxiv, (2022).
    
    

67. 67.Carreno JM, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).
    
    

68. 68.Syed AM, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv, (2022).
    
    

69. 69.Haveri A, et al. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. Eur J Immunol, (2022).
    
    

70. 70.Li M, et al. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Adv, doi:2022.2003.2001.22271662 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2003.2001.22271662&link_type=DOI) 

71. 71.Kurahashi Y, et al. Cross-neutralizing activity against Omicron could be obtained in SARS- CoV-2 convalescent patients who received two doses of mRNA vaccination. medRxiv, doi:2022.2002.2024.22271262 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2002.2024.22271262&link_type=DOI) 

72. 72.Lechmere T, et al. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. mBio 13, e0379821 (2022).
    
    

73. 73.Edara VV, et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep Med 3, 100529 (2022).
    
    

74. 74.Cele S, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).
    
    

75. 75.Wilhelm A, et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. medRxiv, 2021.2012.2007.21267432 (2021).
    
    

76. 76.Doria-Rose NA, et al. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. medRxiv, doi:2021.2012.2015.21267805 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2021.2012.2015.21267805&link_type=DOI) 

77. 77.Kawaoka Y, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Res Sq, (2022).
    
    

78. 78.Dejnirattisai W, et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236 (2022).
    
    

79. 79.Wang Q, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature, (2022).
    
    

80. 80.Khan K, et al. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat Commun 13, 4686 (2022).
    
    

81. 81.Muik A, et al. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5. doi:2022.2008.2002.502461 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2008.2002.502461&link_type=DOI) 

82. 82.Planas D, et al. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection. doi:2022.2007.2022.22277885 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2007.2022.22277885&link_type=DOI) 

83. 83.Yu J, et al. Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. doi:2022.2002.2006.22270533 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=2022.2002.2006.22270533&link_type=DOI) 

84. 84.Tuekprakhon A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422–2433.e2413 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cell.2022.06.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2021.12.24.21268317.atom) 

85. 85.Hachmann NP, et al. Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1 and BA.4/BA.5. N Engl J Med 387, 86–88 (2022).